Skip to main content
OpenTrials

Clinical trial condition

Triple-Negative Breast Carcinoma

Explore clinical trials studying Triple-Negative Breast Carcinoma. Study availability and eligibility vary by location and protocol.

62 public trials 8 recruiting studies
Refine in advanced search Browse all conditions

Triple-Negative Breast Carcinoma trial results

Completed

Veliparib in Combination With Carboplatin and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors

NCT01281150

Conditions
Adult Solid Neoplasm, Breast Diseases, Breast Neoplasms, +16 more
Locations
  • Penn State Milton S Hershey Medical Center Hershey, Pennsylvania, United States
  • UPMC-Magee Womens Hospital Pittsburgh, Pennsylvania, United States
  • University of Pittsburgh Cancer Institute (UPCI) Pittsburgh, Pennsylvania, United States
View Trial Details
Active, Not Recruiting

Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer

NCT02954874

Conditions
Breast Carcinoma In Situ, Breast Carcinoma in Situ, Breast Diseases, +15 more
Locations
  • University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
  • Southern Cancer Center PC-Daphne Daphne, Alabama, United States
  • Southern Cancer Center PC-Mobile Mobile, Alabama, United States
  • Southern Cancer Center PC-Providence Mobile, Alabama, United States
View all 919 locations
View Trial Details
Active, Not Recruiting

Platinum in Treating Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy

NCT02445391

Conditions
Breast Diseases, Breast Neoplasms, Estrogen Receptor Negative, +16 more
Locations
  • Mobile Infirmary Medical Center Mobile, Alabama, United States
  • University of South Alabama Mitchell Cancer Institute Mobile, Alabama, United States
  • Anchorage Associates in Radiation Medicine Anchorage, Alaska, United States
  • Anchorage Radiation Therapy Center Anchorage, Alaska, United States
View all 1024 locations
View Trial Details
Active, Not Recruiting

STEMVAC in Patients With Early Stage Triple Negative Breast Cancer

NCT05455658

Conditions
Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, +21 more
Locations
  • Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Baltimore, Maryland, United States
  • Fred Hutch/University of Washington Cancer Consortium Seattle, Washington, United States
  • University of Wisconsin Carbone Cancer Center Madison, Wisconsin, United States
View Trial Details
Active, Not Recruiting

Testing the Addition of an Anti-cancer Drug, Berzosertib, to the Usual Treatment (Radiation Therapy) for Chemotherapy-Resistant Triple-Negative and Estrogen and/or Progesterone Receptor Positive, HER2 Negative Breast Cancer

NCT04052555

Conditions
Bilateral Breast Carcinoma, Breast Diseases, Breast Neoplasms, +9 more
Locations
  • Mayo Clinic Hospital in Arizona Phoenix, Arizona, United States
  • Mayo Clinic in Arizona Scottsdale, Arizona, United States
  • University of California Davis Comprehensive Cancer Center Sacramento, California, United States
  • Mayo Clinic in Florida Jacksonville, Florida, United States
View all 14 locations
View Trial Details
Active, Not Recruiting

Molecular Testing and Imaging in Improving Response in Patients With Stage I-III Triple-Negative Breast Cancer Receiving Chemotherapy MDACC Breast Moonshot Initiative

NCT02276443

Conditions
Breast Diseases, Breast Neoplasms, Invasive Breast Carcinoma, +16 more
Locations
  • MD Anderson in The Woodlands Conroe, Texas, United States
  • M D Anderson Cancer Center Houston, Texas, United States
  • MD Anderson West Houston Houston, Texas, United States
  • MD Anderson League City League City, Texas, United States
View Trial Details
Active, Not Recruiting

Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer

NCT01116648

Conditions
Adnexal Diseases, Breast Diseases, Breast Neoplasms, +21 more
Locations
  • Cedars-Sinai Medical Center Los Angeles, California, United States
  • University of Chicago Comprehensive Cancer Center Chicago, Illinois, United States
  • NorthShore University HealthSystem-Evanston Hospital Evanston, Illinois, United States
  • Fort Wayne Medical Oncology and Hematology Inc - Jefferson Boulevard Fort Wayne, Indiana, United States
View all 14 locations
View Trial Details
Active, Not Recruiting

Neoadjuvant Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Ca

NCT02957968

Conditions
Breast Adenocarcinoma, Breast Diseases, Breast Neoplasms, +17 more
Locations
  • St. Elizabeth Healthcare Edgewood, Kentucky, United States
  • Ohio State University Comprehensive Cancer Center Columbus, Ohio, United States
  • University of Virginia Charlottesville, Virginia, United States
  • Virginia Commonwealth University/Massey Cancer Center Richmond, Virginia, United States
View Trial Details

Related conditions